KMU Collaborates with GBS to Develop Fast Diagnostic Platform to Screen COVID-19

Report Post

Kaohsiung Medical University (KMU) has signed a memorandum of understanding (MoU) with the General Biologicals Corporation (GBC) to establish a collaboration to fight against COVID-19.

Under the leadership by the Vice President Dr. Ming-Lung Yur. Sheng-Fan Wang from the Department of Medical Laboratory Sciences and Biotechnology and his colleagues Dr.Yeou-Lih Huang, Dr. Yen-Hsu Chen, Dr. Po-Liang Lu, Dr. Shu-Chi Wang, and others, collaborate with GBC to develop an Automatic ELISA fast diagnostic platform for the detection of specific antibody against SARS-CoV-2 viruses.

This automatic COVID-19 ELISA platform can widely and quickly screen a large number of blood samples from suspected cases. The daily screening numbers of this platform is around 1440. Currently, KMU has joined forces together with the National Team to combat COVID-19.

The current diagnostic testing for COVID-19 has relied on labor-intensive molecular techniques (real-time RT-PCR) to detect viral RNA. Antibody testing for SARS-CoV-2 (including IgM and IgG responses), will enable us to not only understand the prevalence and incidence of SARS-CoV-2 infections but also can be a reference for future COVID-19 vaccination.